By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Everist Genomics today said that it has received the US Clinical Laboratory Improvement Amendment certification required for it to launch its OncoDefender-CRC assay.

The Ann Arbor, Mich.-based firm plans to officially launch the test, which is a gene-based assay used in stage I and II colon cancer and stage I rectal cancer patients to assess the risk of recurrence following surgery, later this month.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Social media is changing how scientists discuss research, as tweets from University of Chicago's Yoav Gilad about a Mouse ENCODE paper have shown, Nature reports.

In Nature this week: factors affecting the success of whole-genome sequencing for routine clinical diagnosis, and more.

A large meta-analysis from an international team reports that nature and nurture have about an equal overall influence on human traits.

The Lasker Foundation's Claire Pomeroy laments the state of NIH funding at Forbes.